Institute of Oncology of Southern Switzerland (IOSI), Bellinzona, Switzerland; Breast Unit of Southern Switzerland (CSSI), Lugano, Switzerland.
Department of Internal Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Chin Clin Oncol. 2020 Apr;9(2):18. doi: 10.21037/cco.2020.01.07. Epub 2020 Feb 4.
Bone is one of the most common metastatic sites in metastatic breast cancer (mBC). The presence of bone metastases can lead to various complications including pain, spinal cord compression, hypercalcaemia, pathological fractures. The treatment of bone metastases of breast cancer (BC) is mainly based on the biological characteristics of the primary tumour, but there are also specific treatments for bone lesions including bone modifiers, radionuclides, or localized treatments such as radiotherapy, surgery or vertebroplasty. In this review, we analyse the state of art of the common treatments and the advances of bone metastases of BC. Finally, we summarize the state of art of biomarkers in diagnosis, prognosis and prediction to therapy.
骨骼是转移性乳腺癌（mBC）中最常见的转移部位之一。骨转移的存在可导致各种并发症，包括疼痛、脊髓压迫、高钙血症、病理性骨折。乳腺癌（BC）骨转移的治疗主要基于原发肿瘤的生物学特性，但也有针对骨病变的特定治疗方法，包括骨调节剂、放射性核素或局部治疗，如放疗、手术或椎体成形术。在这篇综述中，我们分析了 BC 骨转移的常见治疗方法和进展。最后，我们总结了诊断、预后和预测治疗的生物标志物的最新进展。
